Four small IPOs priced this past week, joined by two SPACs. The biggest news came from software provider ServiceTitan (TTAN), which kicked off the roadshow for its $480 million offering. It’s expected to price in the week ahead. ...read more
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, raised $11 million by offering 2.8 million shares at $4, the low end of the range of $4 to $5. Jupiter is developing a unique resveratrol platform product primarily...read more
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. In its latest filing, the company also replaced sole bookrunner Spartan Capital Securities with Revere Securities, and...read more
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. The Jupiter, FL-based company now plans to raise $15 million by offering 2.6 million shares at $5.75. The company had...read more
US IPO Weekly Recap: ServiceTitan launches as small issuers slip through the IPO window
Four small IPOs priced this past week, joined by two SPACs. The biggest news came from software provider ServiceTitan (TTAN), which kicked off the roadshow for its $480 million offering. It’s expected to price in the week ahead. ...read more
Neuro-inflammation biotech Jupiter Neurosciences prices IPO at $4, the low end of the range
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, raised $11 million by offering 2.8 million shares at $4, the low end of the range of $4 to $5. Jupiter is developing a unique resveratrol platform product primarily...read more
Neuro-inflammation biotech Jupiter Neurosciences revives $12 million IPO with revised terms
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. In its latest filing, the company also replaced sole bookrunner Spartan Capital Securities with Revere Securities, and...read more
Neuro-inflammation biotech Jupiter Neurosciences revises terms ahead of $15 million IPO
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. The Jupiter, FL-based company now plans to raise $15 million by offering 2.6 million shares at $5.75. The company had...read more